CART 38

Phase 1 Study of Lintivirally Transduced T Cells Engineered to Contain Anti-CD38 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Acute Myeloid Leukemia and Multiple Myeloma

Arms / Cohorts

EXPERIMENTAL: Cohort A Dose Level 1:Relapsed/Refractory Acute Myeloid Leukemia (AML)

Accepting patients

EXPERIMENTAL: Cohort A Dose Level -1:Relapsed/Refractory Acute Myeloid Leukemia (AML)

Accepting patients

EXPERIMENTAL: Cohort A Dose Level 2:Relapsed/Refractory Acute Myeloid Leukemia (AML)

Accepting patients

EXPERIMENTAL: Cohort A Dose Level 3:Relapsed/Refractory Acute Myeloid Leukemia (AML)

Accepting patients

EXPERIMENTAL: Cohort B Dose Level 1:Multiple Myeloma (MM)

Accepting patients

EXPERIMENTAL: Cohort B Dose Level -1:Multiple Myeloma (MM)

Accepting patients

EXPERIMENTAL: Cohort B Dose Level 2:Multiple Myeloma (MM)

Accepting patients

EXPERIMENTAL: Cohort B Dose Level 3:Multiple Myeloma (MM)

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.